Third Time’s the Charm: FDA Approves Replimune’s Tudriqev (RP1) for Advanced Melanoma
Aug 07, 2026
View online
Third Time’s the Charm: FDA Approves Replimune’s Tudriqev (RP1) for Advanced Melanoma
Who Will Write the Next Chapter of Oncology? – CancerWorld
ORR vs OS: The Debate Continues on X
Paolo Ascierto Receives the 2026 SITC Lifetime Achievement Award
PRODIGE-24/CCTG PA6: Tumor Genomics and Adjuvant Chemotherapy in Resected Pancreatic Cancer
Todd Harper: Cancer Council Victoria Calls for Bold Investment to Transform Cancer Care Ahead of 2026 Election
Brooke Shields: From Hollywood Icon to Powerful Skin Health Advocate
Mammo 2026: Global Breast Cancer Virtual Congress
Horizon Europe Earlier and More Precise Palliative Care Grant 2026
Robert L. Fine Cancer Research Foundation Research Grant 2026
Louisiana Oncology Society 2026 Cancer Congress
29th Annual Oncology Symposium for the Healthcare
The Voice of Oncology
Unsubscribe
|
Manage subscription
OncoDaily, P53 Inc.
867 Boylston Street, 5th Floor, Suite 1094, Boston, MA 02116
Copyright (C) 2023-2026. OncoDaily, P53 Inc. All rights reserved.
